Industry News

Biotechnology Industry News

Boston. San Francisco. Beijing?…

July 17th, 2026|FierceBiotech|

Boston. San Francisco. Beijing? The global biotech industry has long been concentrated in a handful of cities. But which emerging hubs could become dominant forces in biotech in the decades ahead?

Boston. San Francisco. Beijing?…

July 17th, 2026|FierceBiotech|

Boston. San Francisco. Beijing? The global biotech industry has long been concentrated in a handful of cities. But which emerging hubs could become dominant forces in biotech in the decades ahead?

GSK has ended development of…

July 17th, 2026|FierceBiotech|

GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the drugmaker.

Dimerix has bought an acute kidney…

July 17th, 2026|FierceBiotech|

Dimerix has bought an acute kidney injury drug from Mission Therapeutics, paying $5 million upfront and committing up to $287 million in milestones for the phase 2-ready asset.

Cue Biopharma is tapping in a new…

July 16th, 2026|FierceBiotech|

Cue Biopharma is tapping in a new chief medical officer and head of R&D in Dominic Borie, M.D., Ph.D., a physician-scientist with over two decades of industry experience.

Cue Biopharma is tapping in a new…

July 16th, 2026|FierceBiotech|

Cue Biopharma is tapping in a new chief medical officer and head of R&D in Dominic Borie, M.D., Ph.D., a physician-scientist with over two decades of industry experience.

Takeda has unveiled more data from…

July 16th, 2026|FierceBiotech|

Takeda has unveiled more data from its phase 3 trials of zasocitinib, demonstrating that the once-daily pill was able to clear or almost clear scalp psoriasis in 75% of patients.

A phase 2 trial of InnoCare…

July 16th, 2026|FierceBiotech|

A phase 2 trial of InnoCare Pharma’s TYK2 inhibitor soficitinib in nonsegmental vitiligo has hit its primary endpoint, clearing the Chinese biotech to advance into the phase 3 part of the study.

Eli Lilly has struck a deal to buy…

July 16th, 2026|FierceBiotech|

Eli Lilly has struck a deal to buy AtaiBeckley for $2.8 billion upfront, continuing its takeover spree to move into a psychedelic mental health sector targeted by companies including Johnson & Johnson.

Lonza explains why early…

July 15th, 2026|FierceBiotech|

Lonza explains why early de-risking has become a strategic imperative for biotech teams working to reach IND with confidence.

Earlier this year, my colleague…

July 15th, 2026|FierceBiotech|

Earlier this year, my colleague Matt Harrington suggested that clinical leaders should stop asking whether their organizations have an “AI strategy”, not because strategy doesn’t matter, but because the question often produces the wrong conversation.

It appears Braveheart Bio isn’t…

July 15th, 2026|FierceBiotech|

It appears Braveheart Bio isn’t going to let Big Pharma take its freedom anytime soon, as the company is aiming for a Nasdaq listing to move its phase 3 cardiovascular drug forward.

Less than a month after locking…

July 15th, 2026|FierceBiotech|

Less than a month after locking down a lease for a new U.S. headquarters, radiotherapy outfit AdvanCell is poised to push its lead prostate cancer candidate into phase 3 development with the help of a

Roche’s biggest bet in the…

July 15th, 2026|FierceBiotech|

Roche’s biggest bet in the Alzheimer’s disease space may be its phase 3-stage amyloid asset, but the Swiss pharma is keeping its options open when it comes to targeting tau.

Attovia Therapeutics has filed for…

July 15th, 2026|FierceBiotech|

Attovia Therapeutics has filed for an IPO to secure funding for assets including a potential challenger to Sanofi and Regeneron’s Dupixent and Galderma’s Nemluvio.